Evidence map›Paper›PMID 31268504›Full record

ArticleJAMA surgery2019

Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.

Atsushi Ogura, Tsuyoshi Konishi, Geerard L Beets, Chris Cunningham, Julio Garcia-Aguilar, Henrik Iversen, Shigeo Toda, In Kyu Lee, Hong Xiang Lee, Keisuke Uehara and 7 more

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter Study
In one paragraph

Article in JAMA surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 120 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 3 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04486131 recruitingnot on this mapstarted 2020, after this paper: background citation

Lateral Nodal Recurrence in Rectal Cancer

TypeobservationalSponsorAmsterdam UMC, location VUmcRan2020 to 2026Enrolled200ConditionsRectal Cancer
NCT05539417 completednot on this map

Snapshot Rectumcarcinoom 2016

TypeobservationalSponsorAmsterdam UMC, location VUmcRan2016 to 2016Enrolled3,107ConditionsRectal Cancer
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 3 syntheses or guidelines pooled it, 251 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 7 countries.

Atsushi OguraDepartment of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Tsuyoshi KonishiDepartment of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Geerard L BeetsDepartment of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Chris CunninghamDepartment of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Julio Garcia-AguilarDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Henrik IversenCenter for Digestive Diseases, Department of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Shigeo TodaDepartment of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan.
In Kyu LeeDepartment of Surgery, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Hong Xiang LeeDepartment of Surgery, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.
Keisuke UeharaDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Peter LeeDepartment of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Hein PutterDepartment of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands.
Cornelis J H van de VeldeDepartment of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Harm J T RuttenDepartment of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Jurriaan B TuynmanDepartment of Surgery, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands.
Miranda KustersDepartment of Surgery, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands.
Lateral Node Study Consortium
Amsterdam University Medical Centers · NLLeiden University Medical Center · NLNagoya University · JPJapanese Foundation For Cancer Research · JPKarolinska Institutet · SEMaastricht University · NLMemorial Sloan Kettering Cancer Center · USOxford University Hospitals NHS Trust · GBSeoul St. Mary's Hospital · KRThe Netherlands Cancer Institute · NLToranomon Hospital · JPUniversity of Adelaide · AUUniversity of Sydney · AU

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Importance: Previously, it was shown in patients with low rectal cancer that a short-axis (SA) lateral node size of 7 mm or greater on primary magnetic resonance imaging (MRI) resulted in a high lateral local recurrence (LLR) rate after chemoradiotherapy or radiotherapy ([C]RT) with total mesorectal excision (TME) and that this risk was lowered by a lateral lymph node dissection (LLND). The role of restaging MRI after (C)RT with regard to LLR risk and which specific patients might benefit from an LLND is not fully understood. Objective: To determine the factors on primary and restaging MRI that are associated with LLR in low rectal cancer after (C)RT and to formulate specific guidelines on which patients might benefit from an LLND. Design, Setting, and Participants: In this retrospective, multicenter, pooled cohort study, patients who underwent surgery for cT3 or cT4 low rectal cancer with a curative intent from 12 centers in 7 countries from January 2009 to December 2013 were included. All patients' MRIs were rereviewed according to a standardized protocol, with specific attention to lateral nodal features. The original cohort included 1216 patients. For this study, patients who underwent (C)RT and had a restaging MRI were selected, leaving 741 for analyses across 10 institutions, including 651 who underwent (C)RT with TME and 90 who underwent (C)RT with TME and LLND. Main Outcomes and Measures: The main purpose was to identify the factors on primary and restaging MRI associated with LLR after (C)RT with TME. Whether high-risk patients might benefit in terms of LLR reduction from an LLND was also studied. Results: Of the 741 included patients, 480 (64.8%) were male, and the mean (SD) age was 60.4 (12.0) years. An SA lateral node size of 7 mm or greater on primary MRI resulted in a 5-year LLR rate of 17.9% after (C)RT with TME. At 3 years, there were no LLRs in 28 patients (29.2%) with lateral nodes that were 4 mm or less on restaging MRI. Nodes that were 7 mm or greater on primary MRI and greater than 4 mm on restaging MRI in the internal iliac compartment resulted in a 5-year LLR rate of 52.3%, significantly higher compared with nodes in the obturator compartment of that size (9.5%; hazard ratio, 5.8; 95% CI, 1.6-21.3; P = .003). Compared with (C)RT with TME alone, treatment with (C)RT with TME and LLND in these unresponsive internal nodes resulted in a significantly lower LLR rate of 8.7% (hazard ratio, 6.2; 95% CI, 1.4-28.5; P = .007). Conclusions and Relevance: Restaging MRI is important in clinical decision making in lateral nodal disease. In patients with shrinkage of lateral nodes from an SA node size of 7 mm or greater on primary MRI to an SA node size of 4 mm or less on restaging MRI, which occurs in about 30% of cases, LLND can be avoided. However, persistently enlarged nodes in the internal iliac compartment indicate an extremely high risk of LLR, and an LLND lowered LLR in these cases.

Indexed as

AgedChemoradiotherapyCohort StudiesDisease-Free SurvivalFemaleHumansInternationalityLymph NodesMagnetic Resonance ImagingMaleMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosis

Identifiers

PMID31268504
PMCPMC6613303
OpenAlexW2954929188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.